Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND, AUGUST 5, 2025  MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) (MOONLAKE OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.

MOONLAKE IMMUNOTHERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

MOONLAKE IMMUNOTHERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE CONTINUED TO MAKE SIGNIFICANT PROGRESS WITH THE DEVELOPMENT OF THE NANOBODY  SONELOKIMAB ACROSS PORTFOLIO OF INDICATIONS, INCLUDING PHASE 3 STUDIES IN HIDRADENITIS SUPPURATIVA (HS), PSORIATIC ARTHRITIS (PSA) AND ADOLESCENT HS, AS WELL AS PHASE 2 STUDIES IN PALMOPLANTAR PUSTULOSIS (PPP) AND AXIAL SPONDYLOARTHRITIS (AXSPA) ANNOUNCED COMPLETION OF ENROLLMENT OF PATIENTS IN THE PHASE 3 PROGRAM IN HS (THE VELA PROGRAM) AND DISCLOSED BASELINE CHARACTERISTICS, REPLICATING THE PHASE 2 MIRA TRIAL PRESENTED AN INTERIM READOUT OF THE PHASE 2 LEDA STUDY IN PPP, HIGHLIGHTING THE POTENTIAL OF SONELOKIMAB IN AN INDICATION WITH CURRENTLY NO APPROVED THERAPEUTICS IN THE US AND EUROPE, AND FURTHER DERISKING THE OVERALL DEVELOPMENT OF SONELOKIMAB ENDED THE FIRST QUARTER WITH $480.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE DEBT SECURITIES AND ANNOUNCED CLOSING OF A DEBT FACILITY, PROVIDING UP TO $500 MILLION IN NON-DILUTIVE FUNDS AND EXTENDING EXPECTED CASH RUNWAY INTO 2028 ZUG, SWITZERLAND, MAY 12, 2025  MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) (MOONLAKE OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025. MATTHIAS BODENSTEDT, CHIEF FINANCIAL OFFICER OF MOONLAKE IMMUNOTHERAPEUTICS, SAID: WE CONTINUE EXECUTING ACROSS OUR PORTFOLIO OF INDICATIONS WITH QUALITY, SPEED AND EFFICIENCY.

MOONLAKE IMMUNOTHERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

MOONLAKEIMMUNOTHERAPEUTICS TO HOST A CAPITAL MARKETS DAY ON TUESDAY, APRIL 29 ZUG, SWITZERLAND, APRIL 25, 2025 MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, WILL HOST A VIRTUAL CAPITAL MARKETS DAY FOR INVESTORS AND ANALYSTS ON TUESDAY, APRIL 29, 2025. THE EVENT WILL HIGHLIGHT RECENT FINANCIAL AND CLINICAL MILESTONES AND PROVIDE FUTURE STRATEGIC UPDATES.

MOONLAKE IMMUNOTHERAPEUTICS TO HOST A CAPITAL MARKETS DAY ON TUESDAY, APRIL 29

ZUG, SWITZERLAND, APRIL 3, 2025  MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE; NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WITH HERCULES CAPITAL, INC. (NYSE:HTGC), A LEADER IN CUSTOMIZED DEBT FINANCING FOR COMPANIES IN THE LIFE SCIENCES AND TECHNOLOGY-RELATED MARKETS, FOR UP TO $500 MILLION IN NON-DILUTIVE CAPITAL, OF WHICH $75 MILLION DRAWN DOWN AT CLOSE AND ADDITIONAL TRANCHES WILL BECOME AVAILABLE UPON ACHIEVEMENT OF CERTAIN PRE-SPECIFIED MILESTONES THAT ARE ALIGNED WITH MOONLAKE'S STRATEGY AND FUNDING NEEDS.

MOONLAKE SECURES UP TO $500 MILLION IN NON-DILUTIVE FINANCING FROM HERCULES CAPITAL AND ANNOUNCES A CAPITAL MARKETS UPDATE ON APRIL 29 TO PROVIDE IMPORTANT CLINICAL UPDATES

ZUG, SWITZERLAND, FEBRUARY26, 2025  MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) (MOONLAKE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING THERAPIES TO ADDRESS SIGNIFICANT UNMET NEEDS IN INFLAMMATORY SKIN AND JOINT DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER31, 2024.

MOONLAKE IMMUNOTHERAPEUTICS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

NEW TRIALS IN THREE NEW INDICATIONS HAVE BEEN INITIATED WITH THE NANOBODY SONELOKIMAB: PHASE 3 VELA-TEEN TRIAL IN ADOLESCENT HIDRADENITIS SUPPURATIVA (HS), PHASE 2 LEDA TRIAL IN PALMOPLANTAR PUSTULOSIS (PPP) AND PHASE 2 S-OLARIS TRIAL IN AXIAL SPONDYLOARTHRITIS (AXSPA) MOONLAKE NOW INDEPENDENTLY RUNNING SEVEN TRIALS IN 2025 ACROSS LARGE DERMATOLOGY AND RHEUMATOLOGY INDICATIONS: ADULT HS, ADOLESCENT HS, PSORIATIC ARTHRITIS (PSA), PPP AND AXSPA PHASE 2 AND PHASE 3 DATA READ-OUTS ACROSS ALL TARGET INDICATIONS EXPECTED IN 2025 (ADULT HS, AND PPP) AND 2026 (ADOLESCENT HS, PSA AND AXSPA) DATA FROM THE PHASE 3 VELA-TEEN TRIAL MAY BE COMBINED WITH THE PHASE 3 VELA PROGRAM IN ADULTS WITH MODERATE-TO-SEVERE HS TO SUPPORT THE FIRST BIOLOGICS LICENSE APPLICATION (BLA)FOR THE NANOBODY SONELOKIMAB ZUG, SWITZERLAND, JANUARY 8, 2025  MOONLAKE IMMUNOTHERAPEUTICS (MOONLAKE; NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT PATIENTS HAVE BEEN SCREENED IN THREE NEW TRIALS ACROSS THREE NEW INDICATIONS TO EVALUATE SONELOKIMAB, AN INVESTIGATIONAL NANOBODY DESIGNED TO TREAT INFLAMMATORY DISEASE. THE CLINICAL PROGRAM FOR SONELOKIMAB NOW INCLUDES PATIENTS WITH ADOLESCENT HIDRADENITIS SUPPURATIVA (HS), PALMOPLANTAR PUSTULOSIS (PPP) AND AXIAL SPONDYLOARTHRITIS (AXSPA), IN ADDITION TO ADULT PATIENTS WITH HS AND ACTIVE PSORIATIC ARTHRITIS (PSA).

MOONLAKE INITIATES THREE NEW CLINICAL TRIALS AND FURTHER EXPANDS THE PORTFOLIO OF INDICATIONS FOR THE NANOBODY SONELOKIMAB

MOONLAKE IMMUNOTHERAPEUTICS TO HOST A CAPITAL MARKETS UPDATE ON WEDNESDAY, SEPTEMBER 11 ZUG, SWITZERLAND, SEPTEMBER 9, 2024  MOONLAKE IMMUNOTHERAPEUTICS AG (MOONLAKE; NASDAQ: MLTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, WILL HOST A CAPITAL MARKETS UPDATE FOR INVESTORS AND ANALYSTS LIVE FROM NEW YORK ON WEDNESDAY, SEPTEMBER 11 FROM 2024, FROM 9:00  10:30 EST/06:00  08:30 PST/14:00  16:30 CET THE EVENT WILL PROVIDE BUSINESS UPDATES FROM MOONLAKE'S CEO JORGE SANTOS DA SILVA, CSO KRISTIAN REICH AND CFO MATTHIAS BODENSTEDT AND INCLUDE DETAILS ON THE PHASE 3 PROGRAMS FOR OUR INVESTIGATIONAL NANOBODY SONELOKIMAB (SLK) IN HIDRADENITIS SUPPURATIVA (HS) AND PSORIATIC ARTHRITIS (PSA). IN ADDITION, MOONLAKE WILL PROVIDE PIPELINE UPDATES AND DETAILS ON ADDITIONAL CATALYSTS FOR THE 2024-2026 PERIOD, INCLUDING FOR TRIALS IN NEW INDICATIONS SUCH AS THE PHASE 2 TRIALS OF SLK IN PALMO-PLANTAR PUSTULOSIS (PPP).

MOONLAKE IMMUNOTHERAPEUTICS TO HOST A CAPITAL MARKETS UPDATE ON WEDNESDAY, SEPTEMBER 11

MOONLAKE IMMUNOTHERAPEUTICS STARTS PHASE 3 VELA PROGRAM OF THE NANOBODY  SONELOKIMAB IN PATIENTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA

MOONLAKE IMMUNOTHERAPEUTICS STARTS PHASE 3 VELA PROGRAM OF THE NANOBODY SONELOKIMAB IN PATIENTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA

MOONLAKE IMMUNOTHERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE ANNOUNCED POSITIVE FEEDBACK FROM BOTH FDA AND EMA ON THE REGULATORY PATH FOR THE PHASE 3 PROGRAM OF THE NANOBODY  SONELOKIMAB IN HIDRADENITIS SUPPURATIVA (HS) AND OUTLINED THE DEVELOPMENT PLAN WITH TOPLINE RESULTS ANTICIPATED IN MID-2025 REPORTED SIGNIFICANT IMPROVEMENTS OBSERVED ACROSS ALL KEY OUTCOMES WITH SONELOKIMAB OVER 24 WEEKS IN THE ARGO PHASE 2 TRIAL IN ACTIVE PSORIATIC ARTHRITIS (PSA) INCLUDING UNPRECEDENTED MULTI-DOMAIN RESPONSES ACROSS JOINTS, SKIN AND OTHER DOMAINS, SUPPORTING POTENTIAL BEST-IN-CLASS PROFILE OF SONELOKIMAB ANNOUNCED THE IMMINENT COMMENCEMENT OF FOUR ADDITIONAL CLINICAL TRIALS OF SONELOKIMAB ACROSS DERMATOLOGY, AND RHEUMATOLOGY, INCLUDING INNOVATIVE TRIALS IN PALMO-PLANTAR PUSTULOSIS (PPP), JUVENILE HS AND SERONEGATIVE SPONDYLOARTHRITIS ENDED THE FIRST QUARTER WITH $547.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE DEBT SECURITIES, EXPECTED TO SUPPORT A ROADMAP RICH IN POTENTIAL CATALYSTS AND A CASH RUNWAY TO THE END OF 2026 ZUG, SWITZERLAND, MAY 7, 2024  MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) (MOONLAKE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON CREATING NEXT-LEVEL THERAPIES FOR INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2024. DR. JORGE SANTOS DA SILVA, CHIEF EXECUTIVE OFFICER OF MOONLAKE IMMUNOTHERAPEUTICS, SAID: 2024 IS SHAPING UP TO BE A STRONG YEAR FOR MOONLAKE.

MOONLAKE IMMUNOTHERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

MOONLAKE IMMUNOTHERAPEUTICS INKS THREE-YEAR TECHNOLOGY PARTNERSHIP WITH KOMODO HEALTH TO ADVANCE RESEARCH ON INFLAMMATORY SKIN AND JOINT CONDITIONS

MoonLake Immunotherapeutics

MLTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MoonLake Immunotherapeutics

MLTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MLTX